Company intelligence / Profile preview

Tavotek Biotherapeutics

Lower Gwynedd, Pennsylvania, United Statestavotek.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Tavotek has multiple assets in clinical development. TAVO101 is in Phase 2 for severe atopic dermatitis. TAVO412 (a multispecific biologic targeting EGFR, VEGF, and c-Met) and TAVO421 are in Phase 1 for solid tumors. The company has successfully dosed patients in clinical trials for TAVO103A and TAVO101, transforming it from a preclinical to a clinical-stage company.

Therapeutic areas: OncologyImmunologyDermatologyPulmonology
Modalities: Monoclonal antibodiesBispecific antibodiesTrispecific antibodiesAntibody Fragment-Drug Conjugates (FDCs)Bispecific T-cell Engager (BiTE)
Industry: Biotech

Drug pipeline

15 assets

Tavo101

14 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tavotek Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tavotek Biotherapeutics.

Explore the full profile